Suggested remit - To appraise the clinical and cost effectiveness of abemaciclib within its marketing authorisation for treating hormone-receptor positive, HER2-negative breast cancer.
Status In progress
Process STA pre-2018
ID number 1339

Provisional Schedule

Committee meeting: 1 08 January 2019
Expected publication 26 June 2019

Project Team

Project lead Gemma Barnacle

Email enquiries


Companies sponsors Eli Lilly (abemaciclib)
Others Department of Health
  NHS England
  NHS Newbury and District CCG
  NHS Sheffield CCG
  Welsh Government
Patient carer groups Black Health Agency
  Breast Cancer Care
  Breast Cancer Now
  Breast Cancer UK
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  Wellbeing of Women
Professional groups Association of Anaesthetists
  Association of Breast Surgery
  Association of Cancer Physicians
  Association of Surgeons of Great Britain & Ireland
  British Association of Surgical Oncology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  Cancer Research UK
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Breast Cancer Group
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Assessment group Against Breast Cancer
  Breast Cancer Hope
  Breast Cancer Research Trust
  Cochrane Breast Cancer Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Pro-Cancer Research Fund
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (capecitabine, docetaxel, exemestane, gemcitabine, paclitaxel, vinorelbine)
  Amneal Pharma Europe Limited (exemestane)
  AstraZeneca (fulvestrant)
  Aurobindo Pharma (tamoxifen)
  Celgene (paclitaxel)
  Consilient Health (exemestane)
  Dr Reddy’s Laboratories (capecitabine)
  Eli Lilly (gemcitabine)
  Hospira UK (docetaxel, gemcitabine, paclitaxel)
  Medac (capecitabine, docetaxel, paclitaxel, vinorelbine)
  Mylan (capecitabine, exemestane, tamoxifen)
  Novartis Pharmaceuticals (everolimus, ribociclib)
  Pfizer (exemestane, palbociclib)
  Pierre Fabre (vinorelbine)
  Roche (capecitabine)
  Sanofi (docetaxel)
  Seacross Pharmaceuticals (docetaxel)
  Teva UK (docetaxel, exemestane, gemcitabine, paclitaxel, tamoxifen)
  Wockhardt UK (tamoxifen)
  Zentiva (exemestane)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association for Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
27 July 2018 Invitation to participate
19 October 2017 - 16 November 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
23 September 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance